Klaus Wilhardt - Corporate identity, Design, Logo/navnetræk og designguides
Neuromuscular Drug Development Summit (NMD) - Pharma Journalist
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma picked as Biotech of the Week by Labiotech.eu — NMD Pharma
NMD Pharma
NMD Pharma - PIR International
Company Presentation
NMD Pharma A/S | LinkedIn
Well-financed biotech company to enter the clinic in 2020
Investors — NMD Pharma
NMD Pharma
NMD Pharma — NMD Pharma
NMD Pharma company information, funding & investors | Dealroom.co
Management — NMD Pharma
NMD Pharma, finalist i Life Sciences kategorien - EY Danmark
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
NMD Pharma A/S | LinkedIn
NMD Pharma
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
Nete Huus's email & phone | NMD Pharma ApS's Senior Scientist email
Management — NMD Pharma
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis | MENAFN.COM
NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma company information, funding & investors | Dealroom.co
